ORYZON awarded 1,1 Million EUROS grant to develop its EPIGENETIC LSD1 inhibitors for Acute Leukemia

ORYZON a privately held biotechnology company, announced today that it was awarded a 36 month 1.103.602 Euros grant under the INNPACTO-2012 Collaborative Program from the Ministry of Economy and Competitiveness of the Spanish Government.

A substantial part of the Grant will be devoted to finance the Clinical Phase 1 studies in Acute leukemia of Oryzon’s LSD1 inhibitor that is nearing the end of preclinical development. Clinical activities in Spain will be developed by the hospital Valle de Hebron in Barcelona.

A program overview will be presented by Dr. Tamara MAES, CSO and cofounder of the company at the 2nd Cancer Epigenetics symposium on November 08-09, 2012 in Boston, MA and the 4th World Epigenetics summit December 4-6th, 2012 in London.

ORYZON announced today that it was awarded a 36 month 1.103.602 Euros grant from the INNPACTO-2012 Collaborative Program led by the Ministry of Economy and Competitiveness of the Spanish Government. The grant will be used to fund the development and characterization of Oryzon’s LSD1 inhibitors in hematological malignancies with a particular focus in Acute Myeloid Leukemia. Oryzon is the leader of this collaborative program that involves other Spanish companies and Institutions working on hematological malignancies. The consortium has been funded with 2.775.683 Euros.